Search -

Displaying 521 - 540 of 2498

Sort: Relevancy | Date

Presentation TVT 2016

Severe Chronic Kidney Disease and TAVR: Clinical Management Recommendations

Presenter: Ganesh Manoharan

June 17, 2016

News Featured Fellow

Kusum Lata, MD

Yael L. Maxwell

June 17, 2016

News Industry News

Capricor Therapeutics Reports Positive 12-Month Data from the DYNAMIC Clinical Trial

June 17, 2016

Presentation TVT 2016

TVT 1162: Calcium and the Rising EDP TAVR and Same-Setting PVL Closure

Presenter: Jonathon M. White

June 16, 2016

News Conference News TVT 2016

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

Michael O'Riordan

June 16, 2016

News Daily News

患者在 TAVR 后感染性心内膜炎的死亡率高，应予以更好的预防和治疗

Yael L. Maxwell

June 15, 2016

News Daily News

La Alta Mortalidad que Sobreviene tras una Endocarditis Infecciosa Post-TAVR Justifica Mejores Medidas de Prevención y Tratamiento

Yael L. Maxwell

June 15, 2016

News Daily News

High Mortality Following Infective Endocarditis After TAVR Warrants Better Prevention, Treatment

Yael L. Maxwell

June 15, 2016

News Daily News

Experts Agree: Lower Blood Pressure Is Better, but What’s a Realistic Target?

Todd Neale

June 15, 2016

News Daily News

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Survey of Interventional Cardiologists With Absorb BVS Expertise Gives Snapshot of Attitudes, Usage

Michael O'Riordan

June 14, 2016

News Daily News

MitraClip for Obstructive Hypertrophic Cardiomyopathy? Small Series Raises Hopes

Shelley Wood

June 14, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

Michael O'Riordan

June 14, 2016

News Daily News

胆固醇治疗试验协作再次审视他汀类药物与不良事件之间的关系

Michael O'Riordan

June 13, 2016

News Industry News

Secondary Analysis of EXAMINE Trial Finds Highest Risk of Cardiovascular Death for Patients Previously Hospitalized with Heart Failure

June 13, 2016

News Daily News

La Colaboración de Ensayistas para el Tratamiento del Colesterol Vuelve a Analizar los Episodios Adversos secundarios a las Estatinas

Michael O'Riordan

June 13, 2016

News Daily News

Egos and Experience: Personalized Risk Assessment Works, but Entrenched Beliefs Hinder Implementation

L.A. McKeown

June 13, 2016

News Daily News

Adverse Events Linked with Statins Get a Second Look From Cholesterol Treatment Trialists’ Collaboration

Michael O'Riordan

June 13, 2016

Presentation SOLACI 2016

Denervación Renal - Donde estamos hoy?

Presenter: Humberto Casal Pati?o

June 10, 2016

Advertisement

Severe Chronic Kidney Disease and TAVR: Clinical Management Recommendations

Kusum Lata, MD

Capricor Therapeutics Reports Positive 12-Month Data from the DYNAMIC Clinical Trial

TVT 1162: Calcium and the Rising EDP TAVR and Same-Setting PVL Closure

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

患者在 TAVR 后感染性心内膜炎的死亡率高，应予以更好的预防和治疗

La Alta Mortalidad que Sobreviene tras una Endocarditis Infecciosa Post-TAVR Justifica Mejores Medidas de Prevención y Tratamiento

High Mortality Following Infective Endocarditis After TAVR Warrants Better Prevention, Treatment

Experts Agree: Lower Blood Pressure Is Better, but What’s a Realistic Target?

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Survey of Interventional Cardiologists With Absorb BVS Expertise Gives Snapshot of Attitudes, Usage

MitraClip for Obstructive Hypertrophic Cardiomyopathy? Small Series Raises Hopes

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

胆固醇治疗试验协作再次审视他汀类药物与不良事件之间的关系

Secondary Analysis of EXAMINE Trial Finds Highest Risk of Cardiovascular Death for Patients Previously Hospitalized with Heart Failure

La Colaboración de Ensayistas para el Tratamiento del Colesterol Vuelve a Analizar los Episodios Adversos secundarios a las Estatinas

Egos and Experience: Personalized Risk Assessment Works, but Entrenched Beliefs Hinder Implementation

Adverse Events Linked with Statins Get a Second Look From Cholesterol Treatment Trialists’ Collaboration

Denervación Renal - Donde estamos hoy?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content